Evidence-based Products

Study Claim: Tocomin SupraBio System increases the absorption of tocotrienols by 200-300 per cent. The patented system enhances absorption through the GI tract and lymphatic system. It also ensures consistent absorption and does not depend on dietary fat intake for absorption.

Published: Yuen KH, et al. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int J Pharmaceut 2004; (In Press).

Abstract: A single dose comparative bioavailability study was conducted to evaluate the absorption of tocotrienols from two self-emulsifying formulations. One produced an emulsion that readily lipolysed under in vitro condition (SES-A); the other produced a finer dispersion with negligible lipolysis (SES-B) in comparison with that of a non self-emulsifying formulation in soya oil (NSES-C). The study was conducted according to a three-way crossover design using six healthy human volunteers.

Statistically significant differences were observed between the logarithmic transformed peak plasma concentration (Cmax) and total area under the plasma concentration-time curve (AUC) values of both SES-A and -B compared to NSES-C, indicating that SES-A and -B achieved a higher extent of absorption compared to NSES-C. Moreover, the 90 per cent confidence interval of the AUC values of both SES-A and -B over those of NSES-C was between two and three, suggesting an increase in bioavailability of about two to three times compared to NSES-C.

Both SES-A and SES-B also achieved a faster onset of absorption. However, both SES-A and -B had comparable bioavailability, despite the fact that SES-B was able to form emulsions with a smaller droplet size. Thus, it appeared that both droplet sizes as well as the rate and extent of lipolysis of the emulsion products formed were important for enhancing the bioavailability of the tocotrienols from the self-emulsifying systems.

Potential Applications: The patented, highly bioavailable Tocomin SupraBio System allows greater absorption, thereby achieving therapeutic blood levels at a lower dosage. It is available for dietary supplement formulations.

More Info: Tel: +1 732 906 1901 Email: [email protected] www.carotech.net

Study Claim: Dogs undergoing cancer therapy including surgery, chemotherapy and radiation had improved appetite and body weight when concurrently taking Maitake D-Fraction. Treated dogs also showed signs of immune activation.

Published: Shimada T, et al. Usefulness of anticancer complementary immune therapy with DVM Fraction. J Am Holistic Vet Med Assoc 2004 Jul-Sep; (In Press).

Abstract: This study looked at the effect of Maitake D-Fraction on companion animals with cancer. Twenty-two dogs with solid tumours were treated by surgery, chemotherapy, radiation or a combination of these treatments. Simultaneously, they were given Maitake D-Fraction twice per day at a dose of three drops/kg body weight for more than three months.

In spite of the negative effects of surgery and chemotherapy, the dogs? appetites were maintained or improved with Maitake D-Fraction in 96 per cent of cases. The dogs? body weights were maintained or increased in 91 per cent of cases. Out of 17 cases on which immunologic testing was done, 14 dogs (76 per cent) showed an increase in their lymphocyte fraction in peripheral blood, a sign of immune activation. Also, 12 of 13 dogs with an increase in the lymphocyte fraction also had production of immune-activating cytokines (IL-2 and IFN-y). Eleven of 13 dogs with an increase in the lymphocyte fraction had no recurrence of metastases for 10 months after their diagnosis, and 12 of 13 lived for more than 10 months from diagnosis.

Potential Applications: Maitake D-Fraction, as a supplement or liquid extract, for immune therapy in canine cancer.

More Info: Tel: +1 800 747 7418 www.maitake.com

Study Claim: Rice bran water solubles reduce hyperglycaemia; rice bran fibre concentrates reduce hyperlipidaemia in diabetics.

Published: Qureshi AA, et al. Effects of stabilized rice bran, its soluble and fiber fractions on blood glucose levels, and serum lipid parameters in humans with diabetes mellitus Types I and II. J Nutr Biochem 2002;13:175-87.

Abstract: Stabilised rice bran was treated with carbohydrases and heat to yield rice bran water solubles and rice bran fibre concentrates. Stabilised rice bran and its fractions were fed for 60 days to type 1 and 2 diabetics to determine effects on serum haemoglobin, carbohydrate and lipid parameters.

Type 1 subjects (n = 22, 26 and 20) fed stabilised rice bran, rice bran water solubles and rice bran fibre concentrates plus AHA Step-1 diet reduced glycosylated haemoglobin 1%, 11% and 10%, respectively. Fasting serum glucose levels were reduced with stabilised rice bran (9%), rice bran water solubles (29%) and rice bran fibre concentrates (19%). Type 2 subjects (n = 31 and 26) fed rice bran water solubles and rice bran concentrates plus AHA Step-1 diet decreased glycosylated haemoglobin (15% and 11%) and fasting glucose (33% and 22%). Serum insulin levels increased 4% with rice bran water solubles in both types.

Serum total cholesterol, LDL-cholesterol, apolipoprotein B and triglyceride levels were reduced with rice bran fibre concentrates in the type 1 (10, 16, 10, 7%) and type 2 groups (12, 15, 10, 8%), respectively.

Potential Applications: Solubles powder in drinks, bars and lozenges; Fiber Complex in bars, drinks and low-carb baked goods.

More Info: Tel: +1 916 933 5519 www.ricex.com

Study Claim: Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass in overweight adults.

Published: Gaullier JM, et al. Conjugated linoleic acid supplementation for 1y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 2004 Jun; 79(6):1118-25.

To submit newly published research on your company?s ingredients, please email [email protected] for details.
Abstract: 180 men and women with body mass indexes of 25-30 joined a double-blind, placebo-controlled study, assigned to three groups: CLA free fatty acid (FFA), CLA triacylglycerol, or olive oil placebo. Change in body fat mass (BFM) was the primary outcome. Secondary outcomes included effects of CLA on lean body mass (LBM).

Mean BFM in the CLA triacylglycerol and CLA FFA groups was 8.7% and 6.9%, respectively, lower than placebo group. Subjects on CLA FFA had 1.8% greater LBM than subjects on placebo. LDL increased in the CLA FFA group, HDL decreased in the CLA triacylglycerol group, and lipoprotein(a) increased in both CLA groups.

Potential Applications: Tonalin CLA can be an effective weight-loss supplement.

More Info: US: +1 800 673 3702 Europe: +49 211 7940 9692 Asia: +61 3 9584 4588 www.cognis.com
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.